What is ImpriMed?
Founded in 2017 and headquartered in Palo Alto, California, ImpriMed operates at the vanguard of veterinary biotechnology. The company specializes in collecting systemic information directly from live cancer cells harvested from pet patients. By leveraging proprietary data analytics and laboratory testing, ImpriMed provides veterinarians with actionable insights that facilitate personalized chemotherapy selection. This data-driven methodology significantly improves clinical outcomes by identifying the most effective drug combinations for individual animals, effectively bridging the gap between complex oncology research and practical, bedside veterinary care. Their market position is defined by a unique synthesis of high-throughput screening and artificial intelligence, positioning them as a critical infrastructure provider in the rapidly evolving pet health technology sector.
How much funding has ImpriMed raised?
ImpriMed has raised a total of $31M across 2 funding rounds:
Other Financing Round
$8M
Series A
$23M
Other Financing Round (2021): $8M with participation from E.S. Investments, HG Initiative, Draper Dragon, BonAngels, Translink Investment, Draper Associates, Futureplay, Murex Partners, and Primer Sazze Partners
Series A (2023): $23M led by Samyang Chemical Group (삼양화학그룹, SK Telecom, Murex Partners, and Byucksan
Key Investors in ImpriMed
Samyang Chemical Group
Samyang Chemical Group is a diversified conglomerate with interests in chemicals, IT, and steel, actively fostering innovation through its DREAUM startup investment initiative.
SK Telecom
SK Telecom is a premier telecommunications and technology firm specializing in 5G infrastructure and AI-driven solutions to transform global industry connectivity.
Draper Dragon
Draper Dragon is a cross-border venture capital firm that bridges Silicon Valley and Asia, focusing on early-stage investments in transformative technologies and Web3 ecosystems.
What's next for ImpriMed?
With this latest round of financing, ImpriMed is well-positioned to expand its operational footprint and enhance its diagnostic platform. The strategic focus will likely shift toward scaling its laboratory capacity and deepening its integration with veterinary clinics across North America and beyond. By utilizing the $23M to refine its predictive algorithms and broaden its database of cancer cell responses, the company aims to solidify its leadership in the precision veterinary medicine market. Future growth trajectories will likely involve strategic partnerships with major pharmaceutical entities and the continued development of its proprietary AI-driven diagnostic suite, ensuring that ImpriMed remains the gold standard for evidence-based cancer treatment in the veterinary space.
See full ImpriMed company page
